Effective and targeted latency reversal in CD4⁺ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection

References

• Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665–708. doi:10.1146/annurev.immunol.18.1.665
   PubMed Web of Science ®Google Scholar
• Ismail SD, Pankrac J, Ndashimye E, et al. Addressing an HIV cure in LMIC. Retrovirology. 2021;18:21–39. doi:10.1186/s12977-021-00565-1
   PubMed Web of Science ®Google Scholar
• Veenhuis RT, Abreu CM, Costa PAG, et al. Monocyte-derived macrophages contain persistent latent HIV reservoirs. Nat Microbiol. 2023;8:833–844. doi:10.1038/s41564-023-01349-3
   PubMed Web of Science ®Google Scholar
• Cassol E, Alfano M, Biswas P, et al. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol. 2006;80:1018–1030. doi:10.1189/jlb.0306150
   PubMed Web of Science ®Google Scholar
• Bruner KM, Murray AJ, Pollack RA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016;22:1043–1049. doi:10.1038/nm.4156
   PubMed Web of Science ®Google Scholar
• Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015;16:584–589. doi:10.1038/ni.3152
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023;21:657–670. doi:10.1038/s41579-023-00914-1
   PubMed Web of Science ®Google Scholar
• Lindqvist B, Akusjärvi SS, Sönnerborg A, et al. Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. PLoS Pathog. 2020;16:e1008264. doi:10.1371/journal.ppat.1008264
   PubMed Web of Science ®Google Scholar
• Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651–655. doi:10.1038/9498
   PubMed Web of Science ®Google Scholar
• Prins JM, Jurriaans S, Van Praag RME, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 1999;13:2405–2410. doi:10.1097/00002030-199912030-00012
   PubMed Web of Science ®Google Scholar
• Lévy Y, Losso M, Babiker A, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548–1559. doi:10.1056/NEJMoa0903175
   PubMed Web of Science ®Google Scholar
• Lévy Y, Thiébaut R, Gougeon ML, et al. Effect of intermittent interleukin-2 therapy on CD4 + T-cell counts following antiretroviral cessation in patients with HIV. AIDS. 2012;26:711–720. doi:10.1097/QAD.0b013e3283519214
   PubMed Web of Science ®Google Scholar
• Molina JM, Levy Y, Fournier I, et al. Interleukin-2 before antiretroviral therapy in patients with HIV infection: A randomized trial (ANRS 119). J Infect Dis. 2009;200:206–215. doi:10.1086/599989
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2014;1:e13–e21. doi:10.1016/S2352-3018(14)70014-1
   PubMed Web of Science ®Google Scholar
• Søgaard OS, Graversen ME, Leth S, et al. The depsipeptide Romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015;11:e1005142. doi:10.1371/journal.ppat.1005142
   PubMed Web of Science ®Google Scholar
• Elliott JH, Wightman F, Solomon A, et al. Activation of HIV transcription with short-course Vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014;10:e1004473. doi:10.1371/journal.ppat.1004473
   PubMed Web of Science ®Google Scholar
• Archin NM, Kirchherr JL, Sung JAM, et al. Interval dosing with the HDAC inhibitor Vorinostat effectively reverses HIV latency. J Clin Invest. 2017;127:3126–3135. doi:10.1172/JCI92684
   PubMed Web of Science ®Google Scholar
• Archin NM, Liberty AL, Kashuba AD, et al. Administration of Vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–485. doi:10.1038/nature11286
   PubMed Web of Science ®Google Scholar
• Vibholm L, Schleimann MH, Højen JF, et al. Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection. Clin Infect Dis. 2017;64:1686–1695. doi:10.1093/cid/cix201
   PubMed Web of Science ®Google Scholar
• Banerjee C, Archin N, Michaels D, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012;92:1147–1154. doi:10.1189/jlb.0312165
   PubMed Web of Science ®Google Scholar
• Darcis G, Kula A, Bouchat S, et al. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatin-1 + JQ1 and Ingenol-B + JQ1 to potently reactivate viral gene expression. PLoS Pathog. 2015;11:e1005063. doi:10.1371/journal.ppat.1005063
   PubMed Web of Science ®Google Scholar
• Gutiérrez C, Serrano-Villar S, Madrid-Elena N, et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. 2016;30:1385–1392. doi:10.1097/QAD.0000000000001064
   PubMed Web of Science ®Google Scholar
• Korin YD, Brooks DG, Brown S, et al. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol. 2002;76:8118–8123. doi:10.1128/JVI.76.16.8118-8123.2002
   PubMed Web of Science ®Google Scholar
• French AJ, Natesampillai S, Krogman A, et al. Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2. PLoS Pathog. 2020;16:e1008906. doi:10.1371/journal.ppat.1008906
   PubMed Web of Science ®Google Scholar
• Kulkosky J, Culnan DM, Roman J, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001;98:3006–3015. doi:10.1182/blood.V98.10.3006
   PubMed Web of Science ®Google Scholar
• McMahon DK, Zheng L, Cyktor JC, et al. A phase 1/2 randomized, placebo-controlled trial of romidespin in persons with HIV-1 on suppressive antiretroviral therapy. J Infect Dis. 2021;224:648–656. doi:10.1093/infdis/jiaa777
   PubMed Web of Science ®Google Scholar
• Osuna CE, Lim SY, Kublin JL, et al. Evidence that CD32a does not mark the HIV-1 latent reservoir. Nature. 2018;561:E20–E28. doi:10.1038/s41586-018-0495-2
   PubMed Web of Science ®Google Scholar
• Badia R, Ballana E, Castellví M, et al. CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nat Commun. 2018;9:1–10. doi:10.1038/s41467-018-05157-w
   PubMed Web of Science ®Google Scholar
• Sun W, Gao C, Hartana CA, et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature. 2023;614:309–317. doi:10.1038/s41586-022-05538-8
   PubMed Web of Science ®Google Scholar
• Demoustier A, Gubler B, Lambotte O, et al. In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV-specific. AIDS. 2002;16:1749–1754. doi:10.1097/00002030-200209060-00006
   PubMedGoogle Scholar
• Cohn LB, Chomont N, Deeks SG. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe. 2020;27:519–530. doi:10.1016/j.chom.2020.03.014
   PubMed Web of Science ®Google Scholar
• Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417:95–98. doi:10.1038/417095a
   PubMed Web of Science ®Google Scholar
• Pankrac J, Klein K, McKay PF, et al. A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ Vaccines. 2018;3(1):2–11. doi:10.1038/s41541-017-0040-6
   PubMed Web of Science ®Google Scholar
• Mann JFS, Pankrac J, Klein K, et al. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. EBioMedicine. 2020;59:102853. doi:10.1016/j.ebiom.2020.102853
   PubMed Web of Science ®Google Scholar
• Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37:1530–1534. doi:10.1093/molbev/msaa015
   PubMed Web of Science ®Google Scholar
• McMyn NF, Varriale J, Fray EJ, et al. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. J Clin Invest. 2023;133:e171554. doi:10.1172/JCI171554
   PubMed Web of Science ®Google Scholar
• Spivak AM, Bosque A, Balch AH, et al. Ex vivo bioactivity and HIV-1 latency reversal by ingenol dibenzoate and panobinostat in resting CD4+ T cells from aviremic patients. Antimicrob Agents Chemother. 2015;59:5984–5991. doi:10.1128/AAC.01077-15
   PubMed Web of Science ®Google Scholar
• Prodger JL, Capoferri AA, Yu K, et al. Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda. JCI Insight. 2020;5:e139287. doi:10.1172/jci.insight.139287
   PubMed Web of Science ®Google Scholar
• Prodger JL, Lai J, Reynolds SJ, et al. Reduced frequency of cells latently infected with replication-competent human immunodeficiency virus-1 in virally suppressed individuals living in Rakai, Uganda. Clin Infect Dis. 2017;65:1308–1315. doi:10.1093/cid/cix478
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Søgaard OS, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother. 2013;9:993–1001. doi:10.4161/hv.23800
   PubMed Web of Science ®Google Scholar
• Elliott JH, McMahon JH, Chang CC, et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015;2:e520–e529. doi:10.1016/S2352-3018(15)00226-X
   PubMed Web of Science ®Google Scholar
• Lian X, Seiger KW, Parsons EM, et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe. 2023;31:83–96.e5. doi:10.1016/j.chom.2022.12.002
   PubMed Web of Science ®Google Scholar
• Tenner-Rácz K, Rácz P, Gartner S, et al. Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. Prog AIDS Pathol. 1989;1:29–40.
   PubMedGoogle Scholar
• Vanham G, Penne L, Devalck J, et al. Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol. 2001;117:325–342. doi:10.1046/j.1365-2249.1999.00987.x
   Web of Science ®Google Scholar
• Levesque MC, Moody MA, Hwang KK, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009;6:e1000107. doi:10.1371/journal.pmed.1000107
   PubMed Web of Science ®Google Scholar
• Banga R, Procopio FA, Noto A, et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. 2016;22:754–764. doi:10.1038/nm.4113
   PubMed Web of Science ®Google Scholar
• Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med. 2013;210:143–156. doi:10.1084/jem.20121932
   PubMed Web of Science ®Google Scholar
• Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359–362. doi:10.1038/362359a0
   PubMed Web of Science ®Google Scholar
• Jeger-Madiot R, Heredia M, Graff-Dubois S. Germinal centers B-cell reaction and T follicular helper cells in response to HIV-1 infection. Curr Opin HIV AIDS. 2019;14:246–252. doi:10.1097/COH.0000000000000557
   PubMed Web of Science ®Google Scholar
• Duran-Castells C, Prats A, Oriol-Tordera B, et al. Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination. EBioMedicine. 2023;95:104732. doi:10.1016/j.ebiom.2023.104732
   PubMed Web of Science ®Google Scholar
• Williams JP, Hurst J, Stöhr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014;3:e03821. doi:10.7554/eLife.03821
   PubMed Web of Science ®Google Scholar
• Bruner KM, Wang Z, Simonetti FR, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019;566:120–125. doi:10.1038/s41586-019-0898-8
   PubMed Web of Science ®Google Scholar